Breaking Down SG&A Expenses: Neurocrine Biosciences, Inc. vs Novavax, Inc.

Biotech Giants: Neurocrine vs. Novavax SG&A Expense Trends

__timestampNeurocrine Biosciences, Inc.Novavax, Inc.
Wednesday, January 1, 20141798600019928000
Thursday, January 1, 20153248000030842000
Friday, January 1, 20166808100046527000
Sunday, January 1, 201716990600034451000
Monday, January 1, 201824893200034409000
Tuesday, January 1, 201935410000034417000
Wednesday, January 1, 2020433300000145290000
Friday, January 1, 2021583300000298358000
Saturday, January 1, 2022752700000488691000
Sunday, January 1, 2023887600000468946000
Monday, January 1, 20241007200000
Loading chart...

Data in motion

A Tale of Two Biotechs: SG&A Expenses Over Time

In the competitive world of biotechnology, managing expenses is crucial for success. Neurocrine Biosciences, Inc. and Novavax, Inc. have shown contrasting trends in their Selling, General, and Administrative (SG&A) expenses from 2014 to 2023. Neurocrine Biosciences has seen a staggering increase of nearly 4,800% in SG&A expenses, reflecting its aggressive growth strategy. In contrast, Novavax's expenses have grown by approximately 2,300%, indicating a more conservative approach.

By 2023, Neurocrine's SG&A expenses reached nearly double those of Novavax, highlighting its expansive operational scale. This divergence in financial strategy underscores the different paths these companies have taken in the biotech landscape. As the industry evolves, understanding these financial dynamics offers valuable insights into the strategic priorities of leading biotech firms.

Published by
U.S. Securities and Exchange Commission

Source link
sec.gov

Date published
17 Jan 2025